Oncolys BioPharma, Inc.

Oncolys BioPharma, Inc.

Oncolys BioPharma, Inc.

Overview
Date Founded

2004

Headquarters

Otemachi Kamiya-cho Building, 8/F,5-12-13 Toranomon,Minato-Ku,Tokyo 105-0001

Type of Company

Public

Employees (Worldwide)

29

Industries

Medical Products & Equipment
Biotechnology

Company Description

Oncolys BioPharma, Inc. engages in the research and development of oncolytic viruses, drugs for serious infectious diseases, molecular targeted anti-cancer drugs, and tumor diagnostic agents. It also offers consulting services with regard to the research and development of biotechnology drugs. It operates through the following segments: Pharmaceutical and Diagnostics. The Pharmaceutical segments deals with the research, development, manufacture and sale of pharmaceutical products. The Diagnostics segment consists of the research, development, manufacture and sale of test drug and equipment, as well as the provision of inspection services. The company was founded by Yasuo Urata on March 18, 2004 and is headquartered in Tokyo, Japan.

Executives & Employees

Founder

Director & Head-Business Development

Director & Head-Business Administration

Vice President

Vice President

Special Advisor

Special Advisor

Special Advisor

Board of Directors

Founder at Oncolys BioPharma, Inc.

President, Oncolys USA at Oncolys BioPharma, Inc.

Former President & Chief Executive Officer at PENTAX Corp.

Vice President at Oncolys BioPharma, Inc.

Special Advisor at Oncolys BioPharma, Inc.

Special Advisor at Oncolys BioPharma, Inc.

Vice President at Oncolys BioPharma, Inc.

Director & Head-Business Administration at Oncolys BioPharma, Inc.

Paths to Oncolys BioPharma, Inc.
Potential Connections via
Relationship Science
You
Oncolys BioPharma, Inc.
Recent Transactions
Details Hidden

Oncolys BioPharma, Inc. issued Ordinary Shares

Details Hidden

WONIK CUBE Corp. purchases Oncolys BioPharma, Inc.

Details Hidden

YOUAI purchases Oncolys BioPharma, Inc.

Transaction Advisors
Manager

Advised onOncolys BioPharma, Inc. issued Ordinary Shares

Manager

Advised onOncolys BioPharma, Inc. issued Ordinary Shares

Manager

Advised onOncolys BioPharma, Inc. issued Ordinary Shares

Clients

Medigen Biotechnology Corp. engages in biopharmaceutical research and development. It specializes in the drug development of liver disease and cancer, antibody drug, vaccine, and molecular detection. The company was founded on December 31, 1999 and is headquartered in Taipei, Taiwan.

Key Stats and Financials As of 2017
Market Capitalization
$8.73B
Total Enterprise Value
$5.61B
Earnings Per Share
$-106.23
EBITDA
$-1.08B
EBITDAMargin
-469.96%
Five Year Compounded Annual Growth Rate Of Revenue
-10.4%
Three Year Compounded Annual Growth Rate Of Revenue
99.64%
Total Equity
$2.93B
Net Profit
$-1.09B
Revenue
$229M
Total Debt
$455M
Debt TEV
0.08x
TEVNet Income
-5.14x
Enterprise Value Sales
24.46x
Investments
Details Hidden

Unleash Immuno Oncolytics, Inc. develops oncolytic virus immunotherapy products to treat cancer. Its product is UIO-512. the company is headquartered in Saint Louis, MO.

Investors
Details Hidden
Details Hidden

Medigen Biotechnology Corp. engages in biopharmaceutical research and development. It specializes in the drug development of liver disease and cancer, antibody drug, vaccine, and molecular detection. The company was founded on December 31, 1999 and is headquartered in Taipei, Taiwan.

Details Hidden

NVCC focuses their investment approach on incubating innovative firms. Over half of their investments are in start-up and early-stage companies. All their investments are made through funds. The firm invests in a range of sectors, with close to half in information services, followed by medical. NVCC especially seeks to invest in firms that they identify as having special quality, associated risk factors and the expected capital gains. They actively make foreign investments, in addition to those in Japan.They utilize a two-phase approach when developing their investment projects: pre- and post-investment. During pre-investment stage, they first identify relevant firms through their network. Using in-house research as well as third-party auditor research, they analyze the targeted firms. Following group discussion centered on research, they convene an executive meeting for final decision. In the post-investment stage, they actively support the investee through executive dispatch, management, IPO preparation, marketing, business planning, capital policy and business alliances. Their exit strategy tends to be post-IPO.NVCC conducts twice-yearly ratings on invested firms. Should a firm fall short of expectations, they consider buybacks and mergers and acquisitions actions.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Oncolys BioPharma, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Oncolys BioPharma, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Oncolys BioPharma, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/oncolys-biopharma-inc-1553839
  • https://relationshipscience.com/organization/oncolys-biopharma-inc-1553839